公司產(chǎn)品2024年批簽發(fā)情況如下表：
The company's product 2024 annual batch issuance situation is as follows:
|
序號 Serial No. |
產(chǎn)品名稱 Product Name |
批次 Batch |
|
1 |
無細胞百白破b型流感嗜血桿菌聯(lián)合疫苗 Diphtheria, Tetanus, Acellular Pertussis and Haemophilus influenzae type b combined vaccine |
27 批 27 batch |
|
2 |
23價肺炎球菌多糖疫苗 23-valent pneumococcal polysaccharide vaccine |
11 批 11 batch |
|
3 |
13價肺炎球菌多糖結(jié)合疫苗（破傷風類毒素/白喉類毒素） 13- valent pneumococcal polysaccharide conjugate vaccine(TT/DT) |
22 批 22 batch |
|
4 |
吸附無細胞百白破聯(lián)合疫苗 Diphtheria, Tetanus and Acellular Pertussis combined vaccine，Adsorbed |
4 批 4batch |
| 5 |
凍干b型流感嗜血桿菌結(jié)合疫苗
Haemophilus Influenzae Type b Conjugate Vaccine, Freeze-dried
|
11 批
11 batch
|
| 6 |
凍干人用狂犬病疫苗（人二倍體細胞） Rabies Vaccine (Human Diploid Cell) for Human Use, Freeze-dried |
42 批
42 batch
|
| 7 |
水痘減毒活疫苗 Varicella Vaccine, Live |
3 批
3 batch
|
批簽發(fā)公示：https://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGs
Batch release announcement:https://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGs